US Stock MarketDetailed Quotes
ALXO ALX Oncology
- 1.290
- +0.080+6.61%
Close Nov 21 16:00 ET
- 1.340
- +0.050+3.88%
Post 20:01 ET
68.04MMarket Cap-434P/E (TTM)
1.330High1.210Low449.39KVolume1.220Open1.210Pre Close568.05KTurnover1.44%Turnover RatioLossP/E (Static)52.74MShares17.82552wk High0.50P/B40.15MFloat Cap1.19052wk Low--Dividend TTM31.12MShs Float117.450Historical High--Div YieldTTM9.92%Amplitude1.190Historical Low1.264Avg Price1Lot Size
About ALX Oncology Company
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.
Company Profile
SymbolALXO
Company NameALX Oncology
Listing DateJul 17, 2020
Issue Price19.00
Founded2015
CEOMr. Jason Lettmann
MarketNASDAQ
Employees72
Fiscal Year Ends12-31
Address323 Allerton Avenue
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-650-466-7125
Websitehttp://www.alxoncology.com
Company Executives
- Name
- Position
- Salary
- Jason Lettmann
- Chief Executive Officer and Director
- 4.86M
- Dr. Alan B. Sandler, M.D.
- Chief Medical Officer
- --
- Shelly Pinto
- Senior Vice President, Finance, Interim Chief Financial Officer and Chief Accounting Officer
- --
- Dr. Jaume Pons, PhD
- President and Chief Scientific Officer
- 2.75M
- Dr. Corey S. Goodman,PhD
- Executive Chairman of the Board
- 206.61K
- Rekha Hemrajani, M.B.A.
- Independent Director
- 181.02K
- Scott Garland
- Independent Director
- 105.66K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data